Sunday 11 October 2026
Export all RLYB data to Excel Powerpack
Rallybio Corporation
RLYB Healthcare Biotechnology
In the quarter to June 2026, revenue was flat, EPS grew 535.2% and free cash flow grew 648.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
17.02
0.03
+0.18%
Follow RLYB
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 64.86% | (14.98%) | (15.01%) | (21.17%) |
+8 more TTM periods Free account |
|
| 61.12% | (13.90%) | (13.77%) | (19.32%) | ||
ROIC |
(1,052.03%) | (576.66%) | (641.77%) | (643.67%) | |
Return on Tangible Assets |
48.62% | (15.83%) | (15.74%) | (22.81%) | |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
4.69 | (4.85) | (5.30) | (6.21) | |
Free Cash Flow |
26.71 | (27.59) | (29.81) | (35.00) | |
| Other line items | |||||
Cash ROIC |
14.26% | (28.42%) | (26.46%) | (28.60%) | |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
(0.03) | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 1,951.40% | 2,284.03% | 3,460.98% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 1,893.01% | 1,669.58% | 2,315.58% | |
Share Based Compensation of Revenue |
0.00% | 471.79% | 619.35% | 964.84% | |
Operating CF/Net income |
0.59 | 3.53 | 3.32 | 2.47 | |
Depreciation/Fixed assets |
0.00 | (17.35) | (20.91) | (25.88) | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.15 | 0.15 | 0.12 | |
Operating CF per Share |
4.69 | (4.85) | (5.30) | (6.21) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 |
Columns are period end dates